Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-07 4:07 pm Purchase | 2025-03-05 | 13D | Elicio Therapeutics, Inc. ELTX | Yekaterina Chudnovsky | 9,657,539 48.100% | 9,657,539 (New Position) | Filing History |
| 2025-02-05 11:10 am Purchase | 2025-01-30 | 13G | Elicio Therapeutics, Inc. ELTX | Knoll Capital Management LLC | 630,915 5.200% | 630,915 (New Position) | Filing History |
| 2025-01-07 4:30 pm Purchase | 2023-12-08 | 13G | Elicio Therapeutics, Inc. ELTX | Actyus Private Equity SGIIC, S.A. | 587,818 5.450% | 587,818 (New Position) | Filing History |
| 2024-08-14 5:01 pm Purchase | 2024-08-12 | 13D | Elicio Therapeutics, Inc. ELTX | GKCC LLC | 5,595,108 38.700% | 3,442,341 (+159.90%) | Filing History |
| 2024-07-02 4:39 pm Purchase | 2024-06-28 | 13D | Elicio Therapeutics, Inc. ELTX | GKCC LLC | 2,152,767 19.990% | 109,587 (+5.36%) | Filing History |
| 2024-04-10 4:01 pm Sale | 2024-04-08 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 481,727 4.680% | -117,470 (-19.60%) | Filing History |
| 2024-03-20 9:07 pm Sale | 2024-03-18 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 599,197 5.830% | -90,372 (-13.11%) | Filing History |
| 2024-03-20 4:37 pm Purchase | 2024-03-19 | 13D | Elicio Therapeutics, Inc. ELTX | GKCC LLC | 2,043,180 19.990% | 123,016 (+6.41%) | Filing History |
| 2023-12-27 4:07 pm Unchanged | 2023-12-22 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 689,569 7.120% | 0 (Unchanged) | Filing History |
| 2023-12-26 4:25 pm Purchase | 2023-12-22 | 13D | Elicio Therapeutics, Inc. ELTX | GKCC LLC | 1,920,164 19.990% | 1,213,000 (+171.53%) | Filing History |
| 2023-08-30 5:16 pm Unchanged | 2023-08-28 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 689,569 8.160% | 0 (Unchanged) | Filing History |
| 2023-07-07 09:17 am Purchase | 2023-07-06 | 13G | Elicio Therapeutics, Inc. ELTX | Vifor (International) Ltd. | 199,564 0.020% | 199,564 (New Position) | Filing History |
| 2023-06-14 4:04 pm Purchase | 2023-06-01 | 13D | Elicio Therapeutics, Inc. ELTX | Elicio Therapeutics Inc. ELTX | 319,527 3.700% | 319,527 (New Position) | Filing History |
| 2023-06-14 2:42 pm Purchase | 2023-06-01 | 13D | Elicio Therapeutics, Inc. ELTX | GKCC LLC | 707,164 8.400% | 707,164 (New Position) | Filing History |
| 2023-06-12 4:01 pm Purchase | 2023-06-09 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 689,569 7.110% | 689,569 (New Position) | Filing History |
| 2023-02-14 4:23 pm Purchase | 2022-12-31 | 13G | Angion Biomedica Corp. ANGN | Goldberg Itzhak | 180,929 6.000% | 180,929 (New Position) | Filing History |
| 2023-02-14 12:12 pm Unchanged | 2022-12-31 | 13G | Angion Biomedica Corp. ANGN | EISA-ABC LLC | 172,224 5.700% | 0 (Unchanged) | Filing History |
| 2023-02-10 4:53 pm Purchase | 2022-12-31 | 13G | Angion Biomedica Corp. ANGN | Thomas A. Satterfield, Jr. | 221,338 7.350% | 63,884 (+40.57%) | Filing History |
| 2022-05-19 10:04 am Purchase | 2022-05-17 | 13G | Angion Biomedica Corp. ANGN | Thomas A. Satterfield, Jr. | 157,455 5.300% | 157,455 (New Position) | Filing History |
| 2022-04-27 4:10 pm Sale | 2021-12-31 | 13G | Angion Biomedica Corp. ANGN | Elicio Therapeutics Inc. ELTX | 181,512 6.000% | -108,662 (-37.45%) | Filing History |